ArticleInfection and drug resistance2025
Sulbactam Concentration in Critically Ill Patients with Hospital-Acquired Pneumonia: A Comparisons Stratified by Normal and Augmented Renal Clearance.
Article in Infection and drug resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To investigate the impact of varying renal function on serum sulbactam concentrations and antibiotic efficacy in critically ill patients with hospital-acquired pneumonia (HAP) who exhibit no elevation in serum creatinine levels. Patients and Methods: A prospective observational study was conducted on 23 adult HAP patients in the ICU of Shandong Provincial Hospital who received intravenous cefoperazone/sulbactam, from January 2021 to January 2023. Renal function was estimated using serum creatinine (eGFRcreat) and cystatin C (eGFRcys). An eGFRcreat >130 mL/min or eGFRcys >80 mL/min indicated augmented renal clearance. Serum sulbactam levels were measured at 0 min (pre-dose) and 15, 30, 60, 120, 180, 360, and 480 min after the >6th dose using HPLC-MS/MS. Results: Among all the 23 patients, 10 had an eGFRcreat above 130 mL/min and 9 had an eGFRcys above 80 mL/min. Additionally, 13 patients exhibited an eGFRcreat ranging from 47 to 123 mL/min, and 14 patients had an eGFRcys in the range of 22 to 75 mL/min. In patients with higher estimated glomerular filtration rate (eGFR), regardless of whether it was based on creatinine or cystatin C, the serum sulbactam concentration tend to decrease more rapidly after the end of administration. Patients with higher eGFR also tend to have a shorter half time and lower drug exposure (AUC). Five patients experienced antibiotic treatment failure. The median eGFRcreat and eGFRcys of these 5 patients were both higher than those patients who responded positively to antibiotic therapy, although not statistically significant. Conclusion: Patients with higher eGFR demonstrated decreased levels of sulbactam. Despite the discrepancy in GFR estimated by creatinine and cystatin C, both the two biomarkers yielded similar predictions of variability in serum sulbactam concentration. Currently, there is no evidence in this study indicating that differences in renal function affect treatment outcomes in critically ill patients without elevated creatinine levels. Further research is warranted to explore the influence of varying renal function-related pharmacokinetic fluctuations on antibiotic efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.